BIOMARIN PHARMACEUTICAL INC Financing Cash Flow
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Financing Cash Flow of $3.55 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.74B.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $813.17M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $3.16M, a 10.42% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$2.17M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for fiscal 2025 was -$42.39M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for fiscal 2024 was -$526.45M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for fiscal 2023 was -$18.73M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) financing activities for fiscal 2022 was -$18.65M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.74B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.55B 10-Q · filed 2026-08-06 | $3.55B derived: sum of 3 quarters · filed 2026-08-06 | $3.55B derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $813.17M 10-Q · filed 2026-05-05 | $816.32M derived: sum of 2 quarters · filed 2026-05-05 | $814.15M derived: sum of 3 quarters · filed 2026-05-05 | $809.55M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $988.00K derived: sum of 2 quarters · filed 2026-02-26 | -$3.62M derived: sum of 3 quarters · filed 2026-08-06 | -$42.39M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$6.77M derived: sum of 2 quarters · filed 2026-08-06 | -$45.55M 10-Q · filed 2025-10-28 | -$42.69M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$43.38M 10-Q · filed 2026-08-06 | -$40.52M derived: sum of 3 quarters · filed 2026-08-06 | -$539.65M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$38.78M 10-Q · filed 2026-05-05 | -$35.92M derived: sum of 2 quarters · filed 2026-05-05 | -$535.04M derived: sum of 3 quarters · filed 2026-05-05 | -$522.43M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$496.27M derived: sum of 2 quarters · filed 2026-02-26 | -$483.65M derived: sum of 3 quarters · filed 2026-02-26 | -$526.45M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$499.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$486.51M derived: sum of 2 quarters · filed 2025-10-28 | -$529.31M 10-Q · filed 2025-10-28 | -$518.47M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $12.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$30.18M 10-Q · filed 2025-08-05 | -$19.34M derived: sum of 3 quarters · filed 2026-02-26 | -$20.13M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$42.79M 10-Q · filed 2025-05-02 | -$31.95M derived: sum of 2 quarters · filed 2026-02-26 | -$32.74M derived: sum of 3 quarters · filed 2026-02-26 | -$20.78M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.05M derived: sum of 2 quarters · filed 2026-02-26 | $22.02M derived: sum of 3 quarters · filed 2026-02-26 | -$18.73M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$788.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $11.18M derived: sum of 2 quarters · filed 2024-10-31 | -$29.57M 10-Q · filed 2024-10-31 | -$18.70M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | $11.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$28.78M 10-Q · filed 2024-08-05 | -$17.91M derived: sum of 3 quarters · filed 2025-02-24 | -$10.37M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | -$40.74M 10-Q · filed 2024-04-26 | -$29.87M derived: sum of 2 quarters · filed 2025-02-24 | -$22.33M derived: sum of 3 quarters · filed 2025-02-24 | -$34.11M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $10.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $18.41M derived: sum of 2 quarters · filed 2025-02-24 | $6.63M derived: sum of 3 quarters · filed 2025-02-24 | -$18.65M 10-K · filed 2025-02-24 | |
| 2022-09-30 | $7.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$4.24M derived: sum of 2 quarters · filed 2023-11-02 | -$29.52M 10-Q · filed 2023-11-02 | -$15.12M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | -$11.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$37.06M 10-Q · filed 2023-08-02 | -$22.66M derived: sum of 3 quarters · filed 2024-02-26 | -$23.70M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | -$25.28M 10-Q · filed 2023-04-28 | -$10.88M derived: sum of 2 quarters · filed 2024-02-26 | -$11.91M derived: sum of 3 quarters · filed 2024-02-26 | -$964.00K derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | $14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $13.37M derived: sum of 2 quarters · filed 2024-02-26 | $24.32M derived: sum of 3 quarters · filed 2024-02-26 | -$48.00K 10-K · filed 2024-02-26 | |
| 2021-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $9.92M derived: sum of 2 quarters · filed 2022-10-28 | -$14.44M 10-Q · filed 2022-10-28 | -$380.60M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $10.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$13.41M 10-Q · filed 2022-08-04 | -$379.57M derived: sum of 3 quarters · filed 2023-02-27 | -$376.31M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | -$24.36M 10-Q · filed 2022-04-29 | -$390.52M derived: sum of 2 quarters · filed 2023-02-27 | -$387.26M derived: sum of 3 quarters · filed 2023-02-27 | $176.43M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | -$366.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$362.90M derived: sum of 2 quarters · filed 2023-02-27 | $200.79M derived: sum of 3 quarters · filed 2023-02-27 | $181.12M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $566.94M derived: sum of 2 quarters · filed 2021-10-29 | $547.27M 10-Q · filed 2021-10-29 | $551.32M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | $563.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $544.02M 10-Q · filed 2021-07-30 | $548.06M derived: sum of 3 quarters · filed 2022-02-25 | $546.08M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | -$19.67M 10-Q · filed 2021-04-30 | -$15.63M derived: sum of 2 quarters · filed 2022-02-25 | -$17.60M derived: sum of 3 quarters · filed 2022-02-25 | -$69.36M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $2.07M derived: sum of 2 quarters · filed 2022-02-25 | -$49.69M derived: sum of 3 quarters · filed 2022-02-25 | -$74.67M 10-K · filed 2022-02-25 | |
| 2019-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$53.73M derived: sum of 2 quarters · filed 2020-11-06 | -$78.72M 10-Q · filed 2020-11-06 | -$445.08M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | -$51.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$76.74M 10-Q · filed 2020-08-05 | -$443.10M derived: sum of 3 quarters · filed 2021-02-26 | -$437.95M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | -$24.98M 10-Q · filed 2020-05-01 | -$391.34M derived: sum of 2 quarters · filed 2021-02-26 | -$386.19M derived: sum of 3 quarters · filed 2021-02-26 | -$403.22M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | -$366.36M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | -$361.21M derived: sum of 2 quarters · filed 2021-02-26 | -$378.24M derived: sum of 3 quarters · filed 2021-02-26 | -$388.01M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $5.15M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | -$11.88M derived: sum of 2 quarters · filed 2019-11-04 | -$21.64M 10-Q/A · filed 2019-11-04 | -$8.55M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | -$17.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$26.80M 10-Q · filed 2019-08-02 | -$13.70M derived: sum of 3 quarters · filed 2020-02-27 | $468.24M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | -$9.77M 10-Q · filed 2019-04-29 | $3.33M derived: sum of 2 quarters · filed 2020-02-27 | $485.27M derived: sum of 3 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $495.03M derived: sum of 2 quarters · filed 2020-02-27 | $507.14M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $481.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $494.05M 10-Q · filed 2018-10-26 | |||
| 2017-06-30 | $12.11M 10-Q · filed 2018-08-03 | ||||
| 2016-12-31 | $727.11M 10-K · filed 2019-02-28 | ||||
| 2014-03-31 | $136.96M 10-Q · filed 2014-05-02 | $841.89M derived: sum of 2 quarters · filed 2014-05-02 | $854.19M derived: sum of 3 quarters · filed 2014-05-02 | $869.81M derived: sum of 4 quarters · filed 2014-05-02 | |
| 2013-12-31 | $704.93M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $717.23M derived: sum of 2 quarters · filed 2014-02-26 | $732.85M derived: sum of 3 quarters · filed 2014-02-26 | $746.67M 10-K · filed 2014-02-26 | |
| 2013-09-30 | $12.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $27.92M derived: sum of 2 quarters · filed 2013-10-28 | $41.74M 10-Q · filed 2013-10-28 | $81.31M derived: sum of 4 quarters · filed 2014-05-02 | |
| 2013-06-30 | $15.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $29.44M 10-Q · filed 2013-07-29 | $69.01M derived: sum of 3 quarters · filed 2014-05-02 | $79.31M derived: sum of 4 quarters · filed 2014-05-02 | |
| 2013-03-31 | $13.82M 10-Q · filed 2014-05-02 | $53.39M derived: sum of 2 quarters · filed 2014-05-02 | $63.69M derived: sum of 3 quarters · filed 2014-05-02 | $312.67M derived: sum of 4 quarters · filed 2014-05-02 | |
| 2012-12-31 | $39.56M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $49.87M derived: sum of 2 quarters · filed 2014-02-26 | $298.84M derived: sum of 3 quarters · filed 2014-02-26 | $312.29M 10-K · filed 2014-02-26 | |
| 2012-09-30 | $10.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $259.28M derived: sum of 2 quarters · filed 2013-10-28 | $272.73M 10-Q · filed 2013-10-28 | $283.17M derived: sum of 4 quarters · filed 2014-02-26 | |
| 2012-06-30 | $248.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $262.42M 10-Q · filed 2013-07-29 | $272.87M derived: sum of 3 quarters · filed 2014-02-26 | $280.62M derived: sum of 4 quarters · filed 2014-02-26 | |
| 2012-03-31 | $13.45M 10-Q · filed 2013-04-29 | $23.89M derived: sum of 2 quarters · filed 2014-02-26 | $31.65M derived: sum of 3 quarters · filed 2014-02-26 | $39.55M derived: sum of 4 quarters · filed 2014-02-26 | |
| 2011-12-31 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $18.20M derived: sum of 2 quarters · filed 2014-02-26 | $26.11M derived: sum of 3 quarters · filed 2014-02-26 | $29.34M 10-K · filed 2014-02-26 | $29.00M 10-K · filed 2012-02-22 |
| 2011-09-30 | $7.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-29 | $15.66M derived: sum of 2 quarters · filed 2012-10-29 | $18.89M 10-Q · filed 2012-10-29 | $8.82M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-06-30 | $7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $11.13M 10-Q · filed 2012-08-02 | $1.07M derived: sum of 3 quarters · filed 2013-02-26 | $7.78M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-03-31 | $3.23M 10-Q · filed 2012-04-30 | -$6.83M derived: sum of 2 quarters · filed 2013-02-26 | -$127.00K derived: sum of 3 quarters · filed 2013-02-26 | -$2.40M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2010-12-31 | -$10.07M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$3.36M derived: sum of 2 quarters · filed 2013-02-26 | -$5.64M derived: sum of 3 quarters · filed 2013-02-26 | $3.50M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $6.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $4.43M derived: sum of 2 quarters · filed 2011-10-31 | $13.57M 10-Q · filed 2011-10-31 | $15.02M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-06-30 | -$2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-01 | $6.86M 10-Q · filed 2011-08-01 | $8.31M derived: sum of 3 quarters · filed 2012-02-22 | $13.83M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-03-31 | $9.14M 10-Q · filed 2011-04-29 | $10.59M derived: sum of 2 quarters · filed 2012-02-22 | $16.11M derived: sum of 3 quarters · filed 2012-02-22 | ||
| 2009-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $6.97M derived: sum of 2 quarters · filed 2012-02-22 | -$63.79M 10-K · filed 2012-02-22 | ||
| 2009-09-30 | $5.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-29 | -$65.23M 10-Q · filed 2010-10-29 | |||
| 2009-06-30 | -$70.75M 10-Q · filed 2010-08-04 | ||||
| 2008-12-31 | $22.81M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |